Core Viewpoint - Decibel Cannabis Company Inc. has announced a conditional sale agreement for its property in Creston, British Columbia, and plans to consolidate its cannabis cultivation operations into its facility in Battleford, Saskatchewan, aiming to enhance operational efficiency and long-term profitability [1]. Group 1: Sale Agreement Details - The sale price for the Creston property is approximately $2,500,000, with proceeds allocated to repay part of the company's term debt [1]. - The consolidation of the cultivation facility is expected to generate annual cost savings of $4 million [1]. Group 2: Operational Strategy - The consolidation aligns with the company's focus on optimizing its operating footprint and supporting disciplined, profitable growth [1]. - The company aims to improve production efficiency by concentrating operations into fewer, higher-utilized facilities, thereby reducing complexity and strengthening its cost structure [1]. Group 3: Financial Impact - The transaction is anticipated to strengthen the company's balance sheet and improve production efficiency without impacting revenue outlook [1]. - The consolidation is expected to enhance the company's ability to support brand growth in Canada and its global export business [1].

Core Viewpoint - Decibel Cannabis Company Inc. has granted 11,537,223 stock options to its officers and employees as part of its long-term compensation and employee retention program, with each option exercisable at a price of $0.10 per share, reflecting the closing price on February 10, 2026 [1]. Group 1 - The stock options will vest in three equal annual installments on January 1 in 2027, 2028, and 2029, and will expire on February 10, 2031 [1]. - Decibel is a market leader in premium cannabis and extract manufactured products, focusing on innovation and product quality [1]. - The company operates a processing and manufacturing facility in Calgary, Alberta, and has cultivation facilities in British Columbia, Saskatchewan, and Ontario [1]. Group 2 - Decibel's brands, including General Admission, Qwest, and Standard Issue, are sold across Canada and are beginning to expand into new international markets [1]. - The company emphasizes its commitment to delivering products that delight customers through robust innovation [1].

Core Viewpoint - Decibel Cannabis Company has successfully closed a $61 million credit facility with ATB Financial, which will enhance its financial position and support future growth initiatives [1]. Financing Highlights - The financing includes a $40 million First Lien Term Facility, a $10 million Revolving First Lien Credit Facility, and an $11 million Second Lien Term Facility, collectively aimed at reducing 2026 payment obligations by $5 million and extending debt maturities to February 2030 [1]. - The First Lien Term Facility replaces a previous facility due in January 2027, allowing for normal course principal repayments and a bullet repayment at maturity [1]. - The Revolving First Lien Credit Facility provides immediate access to $3 million, with additional funds available upon meeting certain conditions [1]. Financial Position - The company is now free cash flow positive and has no material near-term debt maturities, positioning it well for continued leadership in the Canadian cannabis market and international expansion [1]. - The return on investment from the AgMedica acquisition exceeds 50% annualized, indicating strong potential for further growth and value creation [1]. Strategic Goals - The financing will enable Decibel to pursue corporate development initiatives and strengthen its balance sheet, allowing for further opportunities to scale and become a leading global cannabis company [1]. - The company operates multiple facilities across Canada and is beginning to extend its reach into international markets [1].

Core Points - Decibel Cannabis Company Inc. held its annual and special meeting of shareholders on December 11, 2025, where all matters submitted for consideration were approved [1][2] Meeting Results - The number of directors elected at the meeting was fixed at four, with Shawn Dym, Nadia Vattovaz, Jakob Ripshtein, and Benjamin Sze elected as directors [8] - MNP LLP was appointed as the Company's auditors, with their remuneration to be fixed by the board of directors [8] - The 2025 Stock Option Plan was reapproved as detailed in the management information circular and proxy statement dated October 30, 2025 [8] - Shareholders authorized the Company to consolidate all issued and outstanding common shares on a basis of up to fifty pre-consolidation shares to one post-consolidation share, with the specific ratio to be determined by the board [8] Company Structure - Following the meeting, Shawn Dym, Nadia Vattovaz, and Jakob Ripshtein were appointed to serve on the Corporation's committees, with Vattovaz as chair of the Audit Committee and Ripshtein as chair of the Governance, Compensation, and Nominating Committee [4] Company Overview - Decibel is a consumer-focused cannabis company committed to innovation and product quality, with leading brands such as General Admission, Qwest, and Vox [5] - The Company operates a processing and manufacturing facility in Calgary, Alberta, and two cultivation facilities in British Columbia and Saskatchewan, along with an EUGMP licensed facility in Ontario [5]

Core Insights - Decibel Cannabis Company Inc. reported strong financial results for the third quarter of 2025, indicating that its growth strategy is effective and that international demand is exceeding supply [2][5][11] Financial Performance - Gross Canadian recreational sales reached CAD 38.97 million for Q3 2025, up from CAD 36.59 million in Q3 2024, marking a 6% increase [4] - Net Canadian recreational sales were CAD 24.51 million, a 3% increase year-over-year [5] - International sales surged to CAD 8.41 million in Q3 2025, compared to CAD 0.31 million in Q3 2024, reflecting a significant growth driven by AgMedica's contributions [4][5] - Total gross revenue for Q3 2025 was CAD 47.38 million, up from CAD 36.90 million in Q3 2024, representing a 28% increase [4] - Adjusted EBITDA for Q3 2025 was CAD 7.27 million, a 40% increase from CAD 5.21 million in Q3 2024 [5][6] Profitability Metrics - Gross profit before fair value adjustments was CAD 15.36 million, with a gross margin of 47% for Q3 2025, down from 53% in Q3 2024 [4][5] - Adjusted net income for Q3 2025 was CAD 3.76 million, compared to CAD 2.06 million in Q3 2024, indicating a year-over-year increase of 82% [6][19] Cash Flow and Capital Management - Free cash flow for Q3 2025 was CAD 1.53 million, a slight decrease from CAD 1.83 million in Q3 2024 [6][19] - Adjusted free cash flow increased to CAD 5.18 million in Q3 2025, up from CAD 2.73 million in Q3 2024 [6][19] Guidance and Market Conditions - The company revised its full-year 2025 guidance for net revenue to approximately CAD 115 million and Adjusted EBITDA to approximately CAD 24 million, down from previous estimates of CAD 130 million and CAD 25 million respectively [8][11] - Factors affecting guidance include the halt of cannabis imports by the German Federal Institute for Drugs and Medical Devices and a strike affecting cannabis distribution in British Columbia [9][11]